{
    "2018-08-16": [
        [
            {
                "time": "2018-01-04",
                "original_text": "Notable Thursday Option Activity: AMAT, AIMT, JNJ",
                "features": {
                    "keywords": [
                        "Option",
                        "Activity",
                        "AMAT",
                        "AIMT",
                        "JNJ"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "HBJ health care panel talks tech innovation, high patient costs",
                "features": {
                    "keywords": [
                        "health",
                        "care",
                        "panel",
                        "tech",
                        "innovation",
                        "patient",
                        "costs"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Trump administration proposes production quota cuts for six opioids",
                "features": {
                    "keywords": [
                        "Trump",
                        "administration",
                        "production",
                        "quota",
                        "cuts",
                        "opioids"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?",
                "features": {
                    "keywords": [
                        "Johnson",
                        "Johnson",
                        "JNJ",
                        "Earnings",
                        "Report"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "A Look at the Performance of Bausch Healthâ€™s Ortho Dermatologics",
                "features": {
                    "keywords": [
                        "Performance",
                        "Bausch",
                        "Health",
                        "Ortho",
                        "Dermatologics"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Add Up The Parts: EQWL Could Be Worth $61",
                "features": {
                    "keywords": [
                        "EQWL",
                        "Worth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diversified"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-17",
                "original_text": "Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for August 17, 2018",
                "features": {
                    "keywords": [
                        "Novo",
                        "Nordisk",
                        "Ex-Dividend",
                        "Date"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation",
                "features": {
                    "keywords": [
                        "Speculative",
                        "Biotech",
                        "Stock",
                        "Amarin",
                        "Corporation",
                        "Geron",
                        "Corporation"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Should Gilead Be Worried About This New Monthly HIV Medication?",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Monthly",
                        "HIV",
                        "Medication"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Most Analysts Are Optimistic about Vertex Pharmaceuticals",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Optimistic",
                        "Vertex",
                        "Pharmaceuticals"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-13",
                "original_text": "See what the IHS Markit Score report has to say about Johnson & Johnson.",
                "features": {
                    "keywords": [
                        "IHS",
                        "Markit",
                        "Score",
                        "report",
                        "Johnson",
                        "Johnson"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}